Curriculum Vitaes

Taku Kato

  (加藤 卓)

Profile Information

Affiliation
Joint Research Laboratory of Clinical Medicine , Fujita Health University
Degree
医学博士(岐阜大学医学部医学系研究科)

J-GLOBAL ID
201801019612715115
researchmap Member ID
B000294073

Research History

 4

Education

 1

Papers

 83
  • Yasuhiro Sakai, Taku Kato, Midori Saito, Michiko Osawa, Kazuya Shinmura, Koichi Seto, Kuniaki Saito, Hiroyasu Ito
    Clinica Chimica Acta, 579 120664-120664, Jan, 2026  
  • Tatsuya Ando, Kouhei Sakurai, Masato Hoshi, Hiroyuki Tezuka, Yasuhiro Sakai, Taku Kato, Hiroyasu Ito
    Immunobiology, 230(6) 153119-153119, Nov, 2025  
  • Kouhei Sakurai, Mako Ochiai, Kanata Kojima, Kento Kato, Tatsuya Ando, Taku Kato, Hiroyasu Ito
    Human cell, 38(6) 158-158, Sep 14, 2025  
    The Switch/Sucrose Nonfermentable (SWI/SNF) complexes are chromatin remodeling factors that consist of multiple protein subunits. Each subunit plays a distinct role in gene regulation and is aberrantly expressed in tumors, such as neuroendocrine neoplasms (NENs). BRG1-associated factor 53B (BAF53B), which is also known as ACTL6B, is a neuron-specific subunit that acts as a regulator during neurogenesis. Because the BAF53B expression pattern in tumors is unknown, the present study investigated the expression in cell lines and tissues. Publicly available transcriptome data indicated that BAF53B mRNA was highly expressed in NEN-derived cell lines. We performed immunohistochemical staining on tissue microarrays of different types of NENs with neuroendocrine (NE) marker expression (n = 117) (small cell lung carcinoma (SCLC)lung carcinoid (LC), gastroenteropancreatic-NEN (GEP-NEN), esophageal neuroendocrine carcinoma (ENEC), medullary thyroid carcinoma (MTC), neuroblastoma (NB), and pheochromocytoma (PHEO)) and non-NENs (n = 178). While few positive cells were observed in many cases of non-NENs (e.g., lung adenocarcinoma), positive expression was found in cases of NENs (SCLC (14/19, 73.7%), LC (12/16, 75.0%), GEP-NEN (4/9, 44.4%), ENEC (1/2, 50.0%), MTC (24/27, 88.9%), NB (18/20, 90.0%), and PHEO (16/24, 66.7%)). In NCI-H889 cells, BAF53B knockdown did not affect the cellular viability, and its effect on NE marker expression was only marginal. However, a gene expression microarray analysis suggested that BAF53B-regulated genes were associated with the development and progression of NENs. Our analysis revealed that BAF53B was an immunohistochemical marker for specific NENs, indicating its potentially important role in the pathogenesis.
  • Kanata Kojima, Kouhei Sakurai, Tatsuya Ando, Yasuhiro Sakai, Mako Ochiai, Taku Kato, Hiroyasu Ito
    Medical Molecular Morphology, in press, 2025  Peer-reviewed
    Prospero homeobox protein 1 (PROX1) is aberrantly expressed in tumors, including neuroendocrine neoplasms (NENs); however, the detailed expression pattern remains elusive. This study aimed to immunohistochemically assess PROX1 expression. Immunohistochemistry (IHC) for PROX1 was performed on tissue microarrays of normal tissues (n = 107), NENs (n = 152) (small cell lung carcinoma [SCLC], lung carcinoid [LC], gastroenteropancreatic-NEN [GEP-NEN], esophageal neuroendocrine carcinoma [ENEC], medullary thyroid carcinoma [MTC], neuroblastoma [NB], and pheochromocytoma [PHEO]), and non-NENs (n = 469). In normal tissues, PROX1 was expressed in lymphatic endothelial cells and a subset of epithelial cells in the gastrointestinal tract and the distal convoluted tubules. In NENs, the positive expression was observed in the nucleus of tumor cells in 19/26 SCLC (73.1%), 13/16 LC (81.3%), 10/15 GEP-NEN (66.7%), 2/2 ENEC (100%), 17/43 MTC (39.5%), 1/25 NB (4.0%), and 0/25 PHEO (0%). Although PROX1 was negative in many non-NENs, our analysis revealed high expression in certain cases with medulloblastoma and one case with juvenile granulosa cell tumor. PROX1 was expressed in specific cases with epithelial NENs and some cases with non-NENs. Analysis of PROX1 should provide insights into the molecular characteristics of distinct tumors.
  • 飯沼 光司, 大澤 華織, 伊藤 裕基, 竹内 慎一, 前川 由佳, 堀江 憲吾, 中根 慶太, 加藤 卓, 水谷 晃輔, 土屋 朋大, 東 敏弥, 村瀬 勝俊, 酒々井 夏子, 宮崎 龍彦, 古家 琢也
    泌尿器科紀要, 70(12) 471-471, Dec, 2024  

Misc.

 19
  • 飯沼 光司, 前川 由佳, 堀江 憲吾, 中根 慶太, 加藤 卓, 水谷 晃輔, 棚橋 裕吉, 川田 紘資, 松尾 政之, 土屋 朋大, 古家 琢也
    移植, 54(総会臨時) 278-278, Sep, 2019  
  • 古家 琢也, 中根 慶太, 村松 由佳, 川, 飯沼 光司, 菱田 勢始, 谷口 友規, 伊藤 祐基, 加藤 大貴, 堀江 憲吾, 加藤 卓, 水谷 晃輔, 土屋 朋大
    日本ミニマム創泌尿器内視鏡外科学会雑誌, 11(1) 91-94, Aug, 2019  
  • 仲野 正博, 飯沼 光司, 加藤 卓, 亀山 紘司, 山口 尊弘, 田中 秀和, 松尾 政之, 古家 琢也
    日本泌尿器科学会総会, 107回 PP2-007, Apr, 2019  
  • 大澤 華織, 竹内 慎一, 飯沼 光司, 前川 由佳, 堀江 憲吾, 加藤 卓, 山田 佳輝, 中根 慶太, 水谷 晃輔, 土屋 朋大, 安田 満, 仲野 正博, 酒々井 夏子
    泌尿器科紀要, 64(12) 524-524, Dec, 2018  
  • Taku Kato, Yutaka Hashimoto, Shigekatsu Maekawa, Marisa Shiina, Mitsuho Imai-Sumida, Pritha Dasgupta, Priyanka Kulkarni, Soichiro Yamamura, Shahana Majid, Sharanjot Saini, Varahram Sharryari, Guoren Deng, Rajvir Dahiya, Yuichiro Tanaka
    JOURNAL OF UROLOGY, 197(4) E164-E164, Apr, 2017  
  • 高木 公暁, 高井 学, 河田 啓, 堀江 憲吾, 菊地 美奈, 加藤 卓, 水谷 晃輔, 清家 健作, 土屋 朋大, 安田 満, 横井 繁明, 仲野 正博, 出口 隆, 酒々井 夏子, 宮崎 龍彦, 石原 哲, 亀井 信吾
    泌尿器科紀要, 62(11) 610-610, Nov, 2016  
  • 加藤 大貴, 加藤 卓, 後藤 高広, 玉木 正義, 米田 尚生, 田中 卓二
    日本泌尿器科学会総会, 104回 PP1-204, Apr, 2016  
  • 仲野 正博, 亀山 紘司, 加藤 卓, 田中 秀和, 加藤 博基, 林 真也, 宇野 裕巳, 菅原 崇, 大宝 和博, 出口 隆
    日本泌尿器科学会総会, 104回 PP1-228, Apr, 2016  
  • Takashi Deguchi, Mitsuru Yasuda, Kyoko Hatazaki, Koji Kameyama, Kengo Horie, Taku Kato, Kohsuke Mizutani, Kensaku Seike, Tomohiro Tsuchiya, Shigeaki Yokoi, Masahiro Nakano, Mutsumasa Yoh
    Emerging Infectious Diseases, 22(1) 142-144, Jan 1, 2016  
  • Yasunori Fujita, Toshio Kojima, Kyojiro Kawakami, Kosuke Mizutani, Taku Kato, Takashi Deguchi, Masafumi Ito
    The Prostate, 75(14) 1568-78, Oct, 2015  Peer-reviewed
    BACKGROUND: The acquisition of drug resistance is one of the most malignant phenotypes of cancer and identification of its therapeutic target is a prerequisite for the development of novel therapy. MicroRNAs (miRNAs) have been implicated in various types of cancer and proposed as potential therapeutic targets for patients. In the present study, we aimed to identify miRNA that could serve as a therapeutic target for taxane-resistant prostate cancer. METHODS: In order to identify miRNAs related to taxane-resistance, miRNA profiling was performed using prostate cancer PC-3 cells and paclitaxel-resistant PC-3 cell lines established from PC-3 cells. Microarray analysis of mRNA expression was also conducted to search for potential target genes of miRNA. Luciferase reporter assay was performed to examine miRNA binding to the 3'-UTR of target genes. The effects of ectopic expression of miRNA on cell growth, tubulin polymerization, drug sensitivity, and apoptotic signaling pathway were investigated in a paclitaxel-resistant PC-3 cell line. RESULTS: The expression of miR-130a was down-regulated in all paclitaxel-resistant cell lines compared with parental PC-3 cells. Based on mRNA microarray analysis and luciferase reporter assay, we identified SLAIN1 as a direct target gene for miR-130a. Transfection of a miR-130a precursor into a paclitaxel-resistant cell line suppressed cell growth and increased the sensitivity to paclitaxel. Lastly, ectopic expression of miR-130a did not affect the polymerized tubulin level, but activated apoptotic signaling through activation of caspase-8. CONCLUSIONS: Our results suggested that reduced expression of miR-130a may be involved in the paclitaxel-resistance and that miR-130a could be a therapeutic target for taxane-resistant prostate cancer patients.
  • 仲野 正博, 田中 秀和, 加藤 卓, 菅原 崇, 清家 健作, 亀山 紘司, 近藤 啓美, 高井 学, 秋田 和利, 大宝 和博, 田中 修, 林 真也, 宇野 裕巳, 横井 繁明, 出口 隆
    日本癌治療学会誌, 50(3) 745-745, Sep, 2015  
  • Kimiaki Takagi, Manabu Takai, Koji Kameyama, Kengo Horie, Mina Kikuchi, Taku Kato, Kosuke Mizutani, Kensaku Seike, Tomohiro Tsuchiya, Mitsuru Yasuda, Shigeaki Yokoi, Natsuko Suzui, Masahiro Nakano, Takashi Deguchi
    Urology case reports, 3(5) 138-40, Sep, 2015  Peer-reviewed
    A 26-year-old woman with gross hematuria was seen in a previous hospital. Magnetic resonance imaging (MRI) showed a tumor at the dome of the urinary bladder with invasion outside of the bladder wall. The patient underwent transurethral resection of the bladder tumor (TUR-BT). From the result of the pathological examination, the tumor was suggested to be carcinosarcoma of the bladder. The patient was then referred to our hospital for treatment. We performed radical cystectomy and ileal conduit diversion. Pathological examination of the excised specimen revealed an inflammatory myofibroblastic tumor as the basis for immunostaining of anaplastic lymphoma kinase (ALK).
  • 河田 啓, 高井 学, 亀山 紘司, 堀江 憲吾, 菊地 美奈, 加藤 卓, 水谷 晃輔, 清家 健作, 土屋 朋大, 横井 繁明, 仲野 正博, 出口 隆, 片桐 恭雄, 酒々井 夏子, 宮崎 龍彦
    泌尿器科紀要, 61(6) 254-254, Jun, 2015  
  • Mina Kikuchi, Koji Kameyama, Kengo Horie, Kosuke Mizutani, Kensaku Seike, Taku Kato, Takashi Sugawara, Tomohiro Tsuchiya, Mitsuru Yasuda, Shigeaki Yokoi, Masahiro Nakano, Takashi Deguchi, Hiroshi Kondo, Yoji Moriyama, Hidetoshi Ehara
    Hinyokika kiyo. Acta urologica Japonica, 60(12) 615-20, Dec, 2014  Peer-reviewed
    The management of urinoma after blunt renal trauma is still controversial, ranging from percutaneous drainage or ureteral stent placement for the symptomatic urinoma and waiting for spontaneous vanishment of the asymptomatic urinoma. We present two cases of symptomatic urinoma and a case of asymptomatic urinoma after renal laceration. All patients underwent selective renal arterial embolization for vascular complications, including active bleeding, pseudoaneurysm and arteriovenous fistula. Urinomas, which had been observed in all cases gradually reduced and vanished 1-24 months later. All cases were successfully managed without catheterization or percutaneous drainage for urinoma.
  • Kosuke Mizutani, Riyako Terazawa, Koji Kameyama, Taku Kato, Kengo Horie, Tomohiro Tsuchiya, Kensaku Seike, Hidetoshi Ehara, Yasunori Fujita, Kyojiro Kawakami, Masafumi Ito, Takashi Deguchi
    Anticancer research, 34(7) 3419-23, Jul, 2014  Peer-reviewed
    BACKGROUND/AIM: Exosomes have been demonstrated to be useful non-invasive biomarkers for several cancers including prostate cancer. Since normal cells also secrete exosomes, isolation of cancer-derived exosomes from blood is a prerequisite for their better understanding. The aim of this study is to establish the method for isolation of prostate cancer-related exosomes from blood. MATERIALS AND METHODS: Exosomes were collected from prostate cancer LNCaP and PC-3 cell lines by ultracentrifugation and by using magnetic beads conjugated with anti-CD9 antibody and anti-prostate-specific membrane antigen (PSMA) antibody. Prostate cancer-related exosomes were also isolated from the plasma of prostate cancer patients by anti-PSMA beads. Isolated exosomes were analyzed by western blotting. RESULTS: Exosomes were isolated from LNCaP cells by ultracentrifugation, contained PSMA and androgen receptor (AR). AR was also detected in exosomes isolated from LNCaP cells by anti-PSMA and anti-CD9 beads, showing that AR is present in prostate cancer-related exosomes. The amount of CD9 in isolated exosomes was much higher in advanced and chemo-resistant prostate cancer patients than in prostate cancer patients without metastasis and healthy volunteers, indicating that patients with aggressive prostate cancer exhibit higher levels of prostate cancer-related exosomes in blood. CONCLUSION: The immunoaffinity-based method we developed is capable of isolating prostate cancer-related exosomes from blood, the use of which will enhance investigation processes on exosomes in prostate cancer.
  • Taku Kato, Hidetoshi Ehara, Kimiaki Takagi, Kengo Horie, Shinichi Hattori, Keita Nakane, Kensaku Seike, Takashi Sugawara, Takahiro Goto, Naruyasu Masue, Masayoshi Tamaki, Yasuhisa Ito, Takashi Deguchi
    Hinyokika kiyo. Acta urologica Japonica, 57(7) 363-6, Jul, 2011  Peer-reviewed
  • Taku Kato, Yoshito Takahashi, Keita Nakane, Shigeaki Yokoi, Hidetoshi Ehara, Ikuo Shinoda, Takashi Deguchi
    Hinyokika kiyo. Acta urologica Japonica, 53(2) 117-9, Feb, 2007  Peer-reviewed

Research Projects

 7

Social Activities

 4